Journal Article
. 2016 May; 4:28.
doi: 10.1186/s40425-016-0132-2.

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

Mira A Patel 1 Jennifer E Kim 1 Debebe Theodros 1 Ada Tam 2 Esteban Velarde 3 Christina M Kochel 2 Brian Francica 2 Thomas R Nirschl 2 Ali Ghasemzadeh 2 Dimitrios Mathios 4 Sarah Harris-Bookman 4 Christopher C Jackson 4 Christina Jackson 4 Xiaobu Ye 4 Phuoc T Tran 2 Betty Tyler 4 Vladimir Coric 5 Mark Selby 5 Henry Brem 1 Charles G Drake 6 Drew M Pardoll 2 Michael Lim 1 
  • PMID: 27190629
  •     42 References
  •     36 citations


Background: Glioblastoma (GBM) is a poorly immunogenic neoplasm treated with focused radiation. Immunotherapy has demonstrated synergistic survival effects with stereotactic radiosurgery (SRS) in murine GBM. GITR is a co-stimulatory molecule expressed constitutively on regulatory T-cells and by effector T-cells upon activation. We tested the hypothesis that anti-GITR monoclonal antibody (mAb) and SRS together would confer an immune-mediated survival benefit in glioma using the orthotopic GL261 glioma model.

Methods: Mice received SRS and anti-GITR 10 days after implantation. The anti-GITR mAbs tested were formatted as mouse IgG1 D265A (anti-GITR (1)) and IgG2a (anti-GITR (2a)) isotypes. Mice were randomized to four treatment groups: (1) control; (2) SRS; (3) anti-GITR; (4) anti-GITR/SRS. SRS was delivered to the tumor in one fraction, and mice were treated with mAb thrice. Mice were euthanized on day 21 to analyze the immunologic profile of tumor, spleen, and tumor draining lymph nodes.

Results: Anti-GITR (1)/SRS significantly improved survival over either treatment alone (p < .0001) with a cure rate of 24 % versus 0 % in a T-lymphocyte-dependent manner. There was elevated intratumoral CD4+ effector cell infiltration relative to Treg infiltration in mice treated with anti-GITR (1)/SRS, as well as significantly elevated IFNγ and IL-2 production by CD4+ T-cells and elevated IFNγ and TNFα production by CD8+ T-cells. There was increased mRNA expression of M1 markers and decreased expression of M2 markers in tumor infiltrating mononuclear cells. The anti-GITR (2a)/SRS combination did not improve survival, induce tumor regression, or result in Treg depletion.

Conclusions: These findings provide preclinical evidence for the use of anti-GITR (1) non-depleting antibodies in combination with SRS in GBM.

Keywords: Antibody; GITR; Gioblastoma; Immune checkpoint; Immunotherapy; Radiation.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S F Slovin, C S Higano, +8 authors, T M Beer.
Ann Oncol, 2013 Mar 29; 24(7). PMID: 23535954    Free PMC article.
Highly Cited.
Brain tumors.
L M DeAngelis.
N Engl J Med, 2001 Jan 11; 344(2). PMID: 11150363
Highly Cited. Review.
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.
Hiroyoshi Nishikawa, Takuma Kato, +6 authors, Hiroshi Shiku.
Cancer Res, 2008 Jul 18; 68(14). PMID: 18632650
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh, François Ghiringhelli, +25 authors, Laurence Zitvogel.
Nat Med, 2007 Aug 21; 13(9). PMID: 17704786
Highly Cited.
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
Sandra Demaria, Noriko Kawashima, +4 authors, Silvia C Formenti.
Clin Cancer Res, 2005 Feb 11; 11(2 Pt 1). PMID: 15701862
Highly Cited.
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells.
Geoffrey L Stephens, Rebecca S McHugh, +5 authors, Ethan M Shevach.
J Immunol, 2004 Oct 08; 173(8). PMID: 15470044
Highly Cited.
Science gone translational: the OX40 agonist story.
Andrew D Weinberg, Nicholas P Morris, +2 authors, Brendan D Curti.
Immunol Rev, 2011 Oct 25; 244(1). PMID: 22017441    Free PMC article.
High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities.
John Wong, Elwood Armour, +12 authors, Theodore L DeWeese.
Int J Radiat Oncol Biol Phys, 2008 Jul 22; 71(5). PMID: 18640502    Free PMC article.
Highly Cited.
Toxicity patterns with immunomodulating antibodies and their combinations.
John B A G Haanen, Hans van Thienen, Christian U Blank.
Semin Oncol, 2015 May 13; 42(3). PMID: 25965360
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.
Andrew B Sharabi, Phuoc T Tran, +2 authors, Theodore L Deweese.
Oncology (Williston Park), 2015 May 17; 29(5). PMID: 25979541    Free PMC article.
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
Brett Schrand, Alexey Berezhnoy, +7 authors, Eli Gilboa.
Cancer Immunol Res, 2014 Jun 19; 2(9). PMID: 24938283    Free PMC article.
Dendritic cells resurrect antigens from dead cells.
M Larsson, J F Fonteneau, N Bhardwaj.
Trends Immunol, 2001 Apr 05; 22(3). PMID: 11286729
Combining radiotherapy and immunotherapy: a revived partnership.
Sandra Demaria, Nina Bhardwaj, William H McBride, Silvia C Formenti.
Int J Radiat Oncol Biol Phys, 2005 Oct 04; 63(3). PMID: 16199306    Free PMC article.
Highly Cited. Review.
Factors predictive of improved overall survival following stereotactic radiosurgery for recurrent glioblastoma.
Shyamal C Bir, David E Connor, +2 authors, Anil Nanda.
Neurosurg Rev, 2015 Apr 14; 38(4). PMID: 25864406
Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression.
Naoko Imai, Hiroaki Ikeda, +5 authors, Hiroshi Shiku.
Cancer Sci, 2009 May 13; 100(7). PMID: 19432889
Coordinated regulation of myeloid cells by tumours.
Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Vincenzo Bronte.
Nat Rev Immunol, 2012 Mar 23; 12(4). PMID: 22437938    Free PMC article.
Highly Cited. Review.
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, +10 authors, Jedd D Wolchok.
PLoS One, 2010 May 11; 5(5). PMID: 20454651    Free PMC article.
Highly Cited.
Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
Zineb Belcaid, Jillian A Phallen, +17 authors, Michael Lim.
PLoS One, 2014 Jul 12; 9(7). PMID: 25013914    Free PMC article.
Highly Cited.
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Daniel T Nagasawa, Frances Chow, +3 authors, Isaac Yang.
Neurosurg Clin N Am, 2012 Mar 24; 23(2). PMID: 22440874
Immunogenic cancer cell death: a key-lock paradigm.
Antoine Tesniere, Lionel Apetoh, +6 authors, Guido Kroemer.
Curr Opin Immunol, 2008 Jun 25; 20(5). PMID: 18573340
Highly Cited. Review.
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
Adam D Cohen, Adi Diab, +9 authors, Alan N Houghton.
Cancer Res, 2006 May 03; 66(9). PMID: 16651447    Free PMC article.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.
Katherine A Murphy, Melissa G Lechner, +10 authors, John R Ohlfest.
Clin Cancer Res, 2012 Jul 12; 18(17). PMID: 22781551    Free PMC article.
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Yannick Bulliard, Rose Jolicoeur, +3 authors, Jennifer L Brogdon.
Immunol Cell Biol, 2014 Apr 16; 92(6). PMID: 24732076
Highly Cited.
Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Shihao Chen, Li-Fen Lee, +12 authors, John C Lin.
Cancer Immunol Res, 2014 Nov 13; 3(2). PMID: 25387892
Highly Cited.
Modulation of GITR for cancer immunotherapy.
David A Schaer, Judith T Murphy, Jedd D Wolchok.
Curr Opin Immunol, 2012 Jan 17; 24(2). PMID: 22245556    Free PMC article.
A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.
G Nocentini, L Giunchi, +5 authors, C Riccardi.
Proc Natl Acad Sci U S A, 1997 Jun 10; 94(12). PMID: 9177197    Free PMC article.
Highly Cited.
Factors influencing survival in high-grade gliomas.
Jan C Buckner.
Semin Oncol, 2004 Feb 07; 30(6 Suppl 19). PMID: 14765378
Highly Cited. Review.
Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.
Il-Kyu Kim, Byung-Seok Kim, +13 authors, Chang-Yuil Kang.
Nat Med, 2015 Aug 19; 21(9). PMID: 26280119
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
Christopher Jackson, Jacob Ruzevick, +2 authors, Michael Lim.
Clin Dev Immunol, 2011 Dec 23; 2011. PMID: 22190972    Free PMC article.
Cancer immunoediting in malignant glioma.
Gavin P Dunn, Peter E Fecci, William T Curry.
Neurosurgery, 2012 Feb 23; 71(2). PMID: 22353795
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.
Stephan Gasser, Sandra Orsulic, Eric J Brown, David H Raulet.
Nature, 2005 Jul 05; 436(7054). PMID: 15995699    Free PMC article.
Highly Cited.
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
David Coe, Shaima Begom, +3 authors, Jian-Guo Chai.
Cancer Immunol Immunother, 2010 May 19; 59(9). PMID: 20480365
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Kuibeom Ko, Sayuri Yamazaki, +7 authors, Shimon Sakaguchi.
J Exp Med, 2005 Sep 28; 202(7). PMID: 16186187    Free PMC article.
Highly Cited.
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
David A Schaer, Sadna Budhu, +8 authors, Jedd D Wolchok.
Cancer Immunol Res, 2014 Jan 15; 1(5). PMID: 24416730    Free PMC article.
Highly Cited.
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.
David G DeNardo, Jairo B Barreto, +4 authors, Lisa M Coussens.
Cancer Cell, 2009 Aug 04; 16(2). PMID: 19647220    Free PMC article.
Highly Cited.
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lei Lu, Xiaobing Xu, +3 authors, Xuan Wang.
J Transl Med, 2014 Feb 08; 12. PMID: 24502656    Free PMC article.
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Jing Zeng, Alfred P See, +18 authors, Michael Lim.
Int J Radiat Oncol Biol Phys, 2013 Mar 07; 86(2). PMID: 23462419    Free PMC article.
Highly Cited.
Danger signals: a time and space continuum.
Mojca Skoberne, Anne-Sophie Beignon, Nina Bhardwaj.
Trends Mol Med, 2004 Jun 05; 10(6). PMID: 15177188
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, +18 authors, National Cancer Institute of Canada Clinical Trials Group.
N Engl J Med, 2005 Mar 11; 352(10). PMID: 15758009
Highly Cited.
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells.
Masahide Tone, Yukiko Tone, +4 authors, Herman Waldmann.
Proc Natl Acad Sci U S A, 2003 Nov 11; 100(25). PMID: 14608036    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Anti-GITR therapy promotes immunity against malignant glioma in a murine model.
Jason Miska, Aida Rashidi, +4 authors, Maciej S Lesniak.
Cancer Immunol Immunother, 2016 Oct 14; 65(12). PMID: 27734112    Free PMC article.
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
Mira A Patel, Jennifer E Kim, +19 authors, Michael Lim.
J Immunother Cancer, 2016 Nov 09; 4. PMID: 27822377    Free PMC article.
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
Andrew S Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim.
Neurotherapeutics, 2017 Mar 05; 14(4). PMID: 28258545    Free PMC article.
Immunotherapy and radiation in glioblastoma.
Solmaz Sahebjam, Andrew Sharabi, +2 authors, Prakash Chinnaiyan.
J Neurooncol, 2017 Jun 02; 134(3). PMID: 28567588
Targeting Malignant Brain Tumors with Antibodies.
Rok Razpotnik, Neža Novak, Vladka Čurin Šerbec, Uros Rajcevic.
Front Immunol, 2017 Oct 11; 8. PMID: 28993773    Free PMC article.
Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities.
Colleen T Curley, Natasha D Sheybani, Timothy N Bullock, Richard J Price.
Theranostics, 2017 Nov 08; 7(15). PMID: 29109764    Free PMC article.
The Imbalance of FOXP3/GATA3 in Regulatory T Cells from the Peripheral Blood of Asthmatic Patients.
Tiantian Chen, Xiaoxia Hou, +4 authors, Guochao Shi.
J Immunol Res, 2018 Jul 18; 2018. PMID: 30013989    Free PMC article.
Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Jonathan E Schoenhals, Taylor R Cushman, +7 authors, James W Welsh.
Front Immunol, 2018 Oct 09; 9. PMID: 30294332    Free PMC article.
T-Regulatory Cells In Tumor Progression And Therapy.
Amit Verma, Rohit Mathur, +3 authors, Bilikere S Dwarakanath.
Cancer Manag Res, 2020 Jan 11; 11. PMID: 31920383    Free PMC article.
Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
Ana Rita Pombo Antunes, Isabelle Scheyltjens, +3 authors, Jo A Van Ginderachter.
Elife, 2020 Feb 06; 9. PMID: 32014107    Free PMC article.
In Vivo Bioluminescence Tomography Center of Mass-Guided Conformal Irradiation.
Zijian Deng, Xiangkun Xu, +12 authors, Ken Kang-Hsin Wang.
Int J Radiat Oncol Biol Phys, 2019 Nov 19; 106(3). PMID: 31738948    Free PMC article.
Tumor-Specific T Cell Activation in Malignant Brain Tumors.
Malte Mohme, Marian Christoph Neidert.
Front Immunol, 2020 Mar 03; 11. PMID: 32117316    Free PMC article.
T lymphocyte-targeted immune checkpoint modulation in glioma.
William James Kelly, Amber Jin Giles, Mark Gilbert.
J Immunother Cancer, 2020 Feb 14; 8(1). PMID: 32051289    Free PMC article.
Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.
Qianquan Ma, Wenyong Long, +5 authors, Rong-Fu Wang.
Front Immunol, 2019 Jan 09; 9. PMID: 30619286    Free PMC article.
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
Sarah Harris-Bookman, Dimitrios Mathios, +18 authors, Michael Lim.
Int J Cancer, 2018 Sep 25; 143(12). PMID: 30248181    Free PMC article.
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
John de Groot, Marta Penas-Prado, +27 authors, Amy B Heimberger.
Neuro Oncol, 2019 Nov 23; 22(4). PMID: 31755915    Free PMC article.
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma.
Karishma R Rajani, Lucas P Carlstrom, +3 authors, Terry C Burns.
Front Oncol, 2019 Mar 12; 8. PMID: 30854331    Free PMC article.
Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas.
Jean Philippe Nesseler, Dorthe Schaue, +4 authors, Philippe Nickers.
Adv Radiat Oncol, 2019 Apr 24; 4(2). PMID: 31011672    Free PMC article.
Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives.
Minfeng Yang, In Young Oh, +2 authors, Jung Sun Yoo.
Cancers (Basel), 2020 Aug 23; 12(9). PMID: 32824974    Free PMC article.
RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.
Stephen J Bagley, Wei-Ting Hwang, +3 authors, Arati S Desai.
J Neurooncol, 2018 Oct 26; 141(1). PMID: 30353265    Free PMC article.
Overexpression of Regulatory T Cell-Related Markers (FOXP3, CTLA-4 and GITR) by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer
Esmat Khalife, Ali Khodadadi, +3 authors, Abdollah Jafarzadeh.
Asian Pac J Cancer Prev, 2018 Nov 30; 19(11). PMID: 30484986    Free PMC article.
Fire in the Smoke: Battling Brain Tumors.
Michael Lim, Christopher M Jackson.
Cerebrum, 2019 Feb 13; 2018. PMID: 30746035    Free PMC article.
Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma.
Roxanne Wouters, Sien Bevers, +2 authors, An Coosemans.
Cancers (Basel), 2020 Dec 31; 13(1). PMID: 33374542    Free PMC article.
Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.
Varun Sasidharan Nair, Reem Saleh, +2 authors, Eyad Elkord.
Cancer Immunol Immunother, 2021 Feb 04; 70(8). PMID: 33532902    Free PMC article.
Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?
Erminia Romano, Jamie Honeychurch, Timothy M Illidge.
Cancers (Basel), 2021 Feb 04; 13(3). PMID: 33530329    Free PMC article.
Neuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma.
Mariano Guardia Clausi, Alexander M Stessin, +2 authors, Samuel Ryu.
Sci Rep, 2021 Mar 05; 11(1). PMID: 33658642    Free PMC article.
Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
Vassilis Genoud, Denis Migliorini.
Int J Mol Sci, 2021 Apr 04; 22(7). PMID: 33800593    Free PMC article.
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.
Zohreh Amoozgar, Jonas Kloepper, +19 authors, Rakesh K Jain.
Nat Commun, 2021 May 13; 12(1). PMID: 33976133    Free PMC article.
Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma.
Mara De Martino, Oscar Padilla, +3 authors, Claire Vanpouille-Box.
Front Oncol, 2021 Jun 08; 11. PMID: 34094969    Free PMC article.
Immunotherapy in Glioblastoma: A Clinical Perspective.
Nicolas Desbaillets, Andreas Felix Hottinger.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359621    Free PMC article.
Optimizing T Cell-Based Therapy for Glioblastoma.
Aida Karachi, Farhad Dastmalchi, +6 authors, Maryam Rahman.
Front Immunol, 2021 Aug 24; 12. PMID: 34421912    Free PMC article.
New Immunotherapeutic Approaches for Glioblastoma.
Gustavo Ignacio Vázquez Cervantes, Dinora F González Esquivel, +2 authors, Verónica Pérez de la Cruz.
J Immunol Res, 2021 Sep 25; 2021. PMID: 34557553    Free PMC article.
Hijacking Sexual Immuno-Privilege in GBM-An Immuno-Evasion Strategy.
Martyn A Sharpe, David S Baskin, Amanda V Jenson, Alexandra M Baskin.
Int J Mol Sci, 2021 Oct 24; 22(20). PMID: 34681642    Free PMC article.
Immunotherapy Resistance in Glioblastoma.
Elaina J Wang, Jia-Shu Chen, +5 authors, Manish K Aghi.
Front Genet, 2022 Jan 04; 12. PMID: 34976006    Free PMC article.
Immunotherapy for glioblastoma: the promise of combination strategies.
Mathilde Bausart, Véronique Préat, Alessio Malfanti.
J Exp Clin Cancer Res, 2022 Jan 27; 41(1). PMID: 35078492    Free PMC article.
Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy.
Ran Gao, Guo-Ping Shi, Jing Wang.
Front Immunol, 2022 Apr 05; 13. PMID: 35371055    Free PMC article.